BOSTON, MA, March 07, 2025 (GLOBE NEWSWIRE) — Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that its subsidiary, Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, has been engaged by Algernon NeuroScience Inc. (“Algernon NeuroScience”) for its planned Regulation A (Reg A) offering. Netcapital Securities plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering.
Algernon NeuroScience has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC), though the offering has not yet been qualified or declared effective by the SEC. Algernon intends to use proceeds from the offering to advance its R&D initiatives.
“We are pleased that Algernon NeuroScience has selected Netcapital Securities as its broker-dealer to provide critical compliance and operational support for this offering,” said Martin Kay, CEO at Netcapital Inc.
“We look forward to working with the team at Netcapital Securities as we advance through the SEC qualification process for our planned Reg A offering,” said Christopher J. Moreau, CEO of Algernon NeuroScience.
The securities referenced in the planned Reg A offering may not be sold, nor may offers to buy be accepted, before the offering statement filed with the SEC is qualified. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offers, solicitations, or sales of securities will be made only by means of an offering circular that meets the requirements of Regulation A.
No money or other consideration is being solicited at this time, and if sent in response, it will not be accepted. There is no assurance that the SEC will qualify the offering or that Algernon NeuroScience will successfully raise capital. Investing in early-stage companies involves significant risks, and prospective investors should carefully review all offering materials and risk disclosures before making an investment decision. An investment in this private placement offering is speculative, illiquid, and involves a high degree of risk, including the potential loss of your entire investment.
Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company’s consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”), a registered national securities association. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA.
About Algernon NeuroScience Inc.
Algernon NeuroScience is a wholly-owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its psychedelic DMT program for stroke and traumatic brain injury (TBI).